<DOC>
	<DOCNO>NCT00061815</DOCNO>
	<brief_summary>The purpose study compare overall survival patient previously-treated metastatic , epidermal growth factor receptor ( EGFR ) -positive colorectal cancer treat oxaliplatin , 5-fluorouracil leucovorin ( FOLFOX4 ) cetuximab FOLFOX4 alone .</brief_summary>
	<brief_title>Study Cetuximab , Oxaliplatin , 5-FU/LV Versus Oxaliplatin , 5-FU/LV Patients With Previously Treated Metastatic , EGFR-Positive Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Documented colorectal cancer EGFRpositive metastatic . Prior irinotecan , alone combination , firstline treatment metastatic disease . A serious uncontrolled medical disorder , opinion Investigator , would impair ability subject receive protocol therapy . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . Known metastasis central nervous system . Symptomatic sensory peripheral neuropathy . More one prior chemotherapy regimen treatment metastatic colorectal cancer . Prior oxaliplatin therapy . Prior cetuximab therapy target EGF pathway . Prior chimerized murine monoclonal antibody therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>